Evidence map›Paper›PMID 37885335›Full record

ArticlePharmacology research & perspectives2023

Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero-Test bile string.

Guoying Tai, Fangming Xia, Cathy Chen, Adrian Pereira, Jill Pirhalla, Xiusheng Miao, Graeme Young, Claire Beaumont, Liangfu Chen

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Guoying TaiDrug Metabolism and Pharmacokinetics, GSK, Collegeville, Pennsylvania, USA.
Fangming XiaDrug Metabolism and Pharmacokinetics, GSK, Collegeville, Pennsylvania, USA.
Cathy ChenDrug Metabolism and Pharmacokinetics, GSK, Collegeville, Pennsylvania, USA.
Adrian PereiraDrug Metabolism and Pharmacokinetics, GSK, Stevenage, Hertfordshire, UK.
Jill PirhallaDrug Metabolism and Pharmacokinetics, GSK, Collegeville, Pennsylvania, USA.
Xiusheng MiaoDrug Metabolism and Pharmacokinetics, GSK, Collegeville, Pennsylvania, USA.
Graeme YoungDrug Metabolism and Pharmacokinetics, GSK, Ware, Hertfordshire, UK.
Claire BeaumontDrug Metabolism and Pharmacokinetics, GSK, Stevenage, Hertfordshire, UK.
Liangfu ChenDrug Metabolism and Pharmacokinetics, GSK, Collegeville, Pennsylvania, USA.ORCID 0009-0007-6389-7918
GlaxoSmithKline (United States) · USNorth Hertfordshire College · GBUniversity of Hertfordshire · GB

Funding

GSK
6 · The paper itself

Abstract

Daprodustat is an oral small molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) approved in Japan and the United States for the treatment of anemia associated with chronic kidney disease. This phase 1, nonrandomized, 2-period, crossover study in 6 healthy men characterized and quantified the metabolites generated after a microtracer IV infusion of 50 μg (125 nCi) [

Indexed as

BarbituratesBileCross-Over StudiesGlycineHumansHydrolasesMaleBarbituratesGlycineGSK1278863Hydrolasesdaprodustatexcretionmetabolismmetabolite structural identificationoral absorptionquantitative characterizationsradioactivity

Identifiers

PMID37885335
PMCPMC10603292
OpenAlexW4387964939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.